130466-38-5
中文名称 | 130466-38-5 |
---|---|
中文同义词 | 化合物 T13285 |
英文名称 | Methanesulfonamide,N-[2-[(2R,12bS)-1,3,4,6,7,12b-hexahydro-2'-oxospiro[2H-benzofuro[2,3-a]quinolizine-2,4'-imidazolidin]-3'-yl]ethyl]-,hydrochloride (1:1) |
英文同义词 | Methanesulfonamide,N-[2-[(2R,12bS)-1,3,4,6,7,12b-hexahydro-2'-oxospiro[2H-benzofuro[2,3-a]quinolizine-2,4'-imidazolidin]-3'-yl]ethyl]-,hydrochloride (1:1);Vatinoxan hydrochloride;L-659066 hydrochloride;MK-467 hydrochloride |
CAS号 | 130466-38-5 |
分子式 | C20H27ClN4O4S |
分子量 | 454.97 |
EINECS号 | |
相关类别 | |
Mol文件 | 130466-38-5.mol |
结构式 |
130466-38-5 性质
储存条件 | Store at -20°C |
---|---|
形态 | 固体 |
颜色 | 白色至米白色 |
水溶解性 | Water : ≥ 133 mg/mL (292.33 mM) |
α2 adrenergic receptor
Vatinoxan alone increases cardiac index and tissue oxygen delivery and has no deleterious adverse effects. Vatinoxan attenuates or prevents dexmedetomidine’s systemic hemodynamic effects in a dose-dependent manner when given simultaneously i.v. but has no effect on the pulmonary outcome in conscious dogs. A 50:1 dose ratio (Vatinoxan:dexmedetomidine) induces the least alterations in cardiovascular function. Vatinoxan dose-dependently attenuates the bradycardia associated with dexmedetomidine, and shortens the sedative effect without altering its quality. Vatinoxan may be useful in attenuating reductions in heart rate in conscious catsadministered dexmedetomidine.
安全信息
更新日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
---|---|---|---|---|---|
2024/08/19 | HY-19057A | Vatinoxan hydrochloride | 1 mg | 3350元 | |
2024/08/19 | HY-19057A | 130466-38-5 Vatinoxan hydrochloride | 130466-38-5 | 5mg | 8500元 |